4.4 Article

Gene of the month: cancer testis antigen gene 1b (NY-ESO-1)

期刊

JOURNAL OF CLINICAL PATHOLOGY
卷 -, 期 -, 页码 -

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/jcp-2023-209053

关键词

CANCER; TESTIS

向作者/读者索取更多资源

CTAG1B/NY-ESO-1, as a member of the cancer testis antigen family, holds promising potential in cancer immunotherapy. This article discusses the structure, function, and immunohistochemical detection of CTAG1B/NY-ESO-1, as well as the latest advances in associated anti-cancer therapies.
Cancer testis antigen gene 1B (CTAG1B) and its associated gene product; New York oesophageal squamous carcinoma 1 (NY-ESO-1), represent a unique and promising target for cancer immunotherapy. As a member of the cancer testis antigen family (CTA), the protein's restricted expression pattern and ability to elicit spontaneous humoural and cellular immune responses has resulted in a plethora of novel modalities and approaches attempting to harness its immunotherapeutic anti-cancer potential. Here, we discuss the structure and function of CTAG1B/NY-ESO-1 in both health and disease, immunohistochemical detection, as well as the most promising advances in the development of associated anti-cancer therapies. From cancer vaccines to engineered cellular therapy approaches, a multitude of immunotherapies targeting CTA's are coming to the forefront of oncology. Although the efficacy of such approaches have yet to provide convincing evidence of durable response, early phase clinical trial data has resulted in some exciting findings which will have significant potential to act as a platform for future practice changing technologies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据